InnFocus MicroShunt® showing promising results in reducing IOP in glaucoma patients.
CHICAGO, Oct. 17, 2014 /PRNewswire/ — InnFocus, Inc., reported on results of 59 glaucoma patients treated outside the United States for up to 3 years with the InnFocus MicroShunt® at the 2014 Ophthalmology Innovation Summit in Chicago. The Summit was held prior to the beginning of the annual meeting of the American Academy of Ophthalmology. The Company also said it expects to have treated approximately 150 glaucoma patients in 6 countries by early 2015.
Logo – http://photos.prnewswire.com/prnh/20141016/152617LOGO
InnFocus President & CEO Russ Trenary made the presentation in front of hundreds of physicians, entrepreneurs, investors and industry executives interested in ophthalmic innovation.
"We are encouraging our audience to 'Think Low' when they consider what IOP levels are possible with the InnFocus MicroShunt®," said Trenary, referring to the results the medical device is producing in treating glaucoma patients.
The device is showing a significant and stable reduction in mean intraocular pressure (IOP) to below 14mmHg in patients thus far. Between 70% and 80% of patients have either reduced the amount of medication they are taking or are off medication completely.
"We also shared with the audience that the InnFocus MicroShunt® addresses the largest patient segment in glaucoma," Trenary added. "We don't need to rely on combining cataract removal to achieve these impressive results."
The InnFocus MicroShunt® is a glaucoma drainage implant consisting of a microtube about the twice the size of an eyelash. It is currently in Phase 1 Food and Drug Administration trials at 11 centers in the United States. Patients have also been treated in France, Japan, and the Dominican Republic.
InnFocus aims to provide a safe, effective, stable and easy treatment for early stage to late stage glaucoma. Glaucoma affects over 78 million persons worldwide, and is the second leading cause of blindness in the world.
The InnFocus MicroShunt® has been implanted alone or in combination with cataract surgery in clinical trials outside the United States. It was developed in collaboration with the University of Miami's Bascom Palmer Eye Institute. It provides a quick and simple method of shunting aqueous humor from the anterior chamber to a diffuse bleb without the use of a scleral flap.
It uses a patented micro-shunt made from the innovative SIBS Material to control flow. The mechanism of action for the MicroShunt of subconjunctival/Tenons drainage has been the accepted gold standard for decades.
CAUTION: INVESTIGATIONAL DEVICE. LIMITED TO INVESTIGATIONAL USE IN THE UNITED STATES.
Media Contact:
Ed Coghlan
InnFocus, Inc.
Email
818-489-4774